Malignant Solid Tumor, Metastatic Cancer, Advanced Cancer
Conditions
Brief summary
This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan. RRx-001 is associated with resensitization to irinotecan in tumors that are previously refractory. This effect has been attributed to the ability of RRx-001 to restore the expression of aberrantly silenced genes, thus re-establishing pathway functions. However, resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular modulation, leading to improved penetration of standard chemotherapy.
Detailed description
This dose escalation study consists of 5 sequential dose cohorts each administered RRx-001 with irinotecan. After the first 3 subjects of each cohort complete Cycle 1, the safety will be assessed before moving to the next dose level. Subjects in the current cohort will continue treatment immediately following the completion of Cycle 1, for as long as therapy is tolerated and the RECIST v.1.1 definition of progression is not met.
Interventions
DRUGRRx-001
DRUGIrinotecan
Sponsors
EpicentRx, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined. * Eastern Cooperative Group (ECOG) performance status is 0-2 at Screening. * Measurable disease per RECIST v1.1 by radiographic techniques * Acceptable liver function, serum creatinine and hematological status * Female subjects of childbearing potential, and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001. * Subjects with brain metastases are eligible
Exclusion criteria
* Concurrent anticancer therapy; however, radiotherapy is allowed * Any history of hypersensitivity to irinotecan * Cholangitis that required treatment or intervention within 4 weeks of study enrollment * Bilirubin \> 2.0 mg/dL * Serious medical or psychiatric illness likely to interfere with participation in this clinical study * If female, subject is pregnant and/or breastfeeding. * UGT1A1\*28 homozygote or heterozygote * BMI \>35
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number, frequency and type of adverse events | 14 Weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of clinical benefit rate | 1 year | Duration of clinical benefit (Stable disease or better) using Response Evaluation Criteria in Solid Tumors \[RECIST v1.1\] criteria |
| Progression-Free Survival | 1 year | Progression-Free Survival (PFS) using Response Evaluation Criteria in Solid Tumors |
| Overall Response rate | 1 year | Proportion of patients with reduction in tumor burden using Response Evaluation Criteria in Solid Tumors |
| Overall Survival | 2 years | — |
Countries
United States
Outcome results
None listed